Study of CM518D1 in Patients With Advanced Solid Tumors

Exclusion Criteria

• •1\. Subjects who have received any chemotherapy or any drug therapy for antitumor treatment including monoclonal antibodies, targeted therapy, radioimmunoconjugates, or Antibody-Drug Conjugates(ADCs), or any investigational product therapy for anti-tumor therapy within 28 days prior to the first dose or within 5 half-lives (whichever is shorter).
• •2\. Subjects who have received major surgery within 28 days prior to the first dose.
• •3\. Subjects who have received radiotherapy within 21 days prior to the first dose.
• •4\. Subjects who have received systemic glucocorticoid therapy (more than 10 mg of prednisone or equivalent daily) or other forms of immunosuppressive therapy within 7 days prior to the first dose.
• •5\. Subjects who have received any CDH17-targeted therapy.
• •6\. History of other malignancies within 5 years prior to the first dose, excluding cured basal or squamous cell carcinoma of skin, carcinoma cervix in situ, or breast ductal carcinoma in situ.
• •7\. Hypersensitivity to the investigational drug or its excipients.
• •8\. Pregnant or lactating female patients.